TOP > 外国特許検索 > NEW MOLECULARLY TARGETED DRUG FOR TREATING MALIGNANT TUMORS

NEW MOLECULARLY TARGETED DRUG FOR TREATING MALIGNANT TUMORS

外国特許コード F160008659
整理番号 (S2014-1065-N0)
掲載日 2016年2月5日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP065749
国際公開番号 WO 2015198797
国際出願日 平成27年6月1日(2015.6.1)
国際公開日 平成27年12月30日(2015.12.30)
優先権データ
  • 特願2014-130925 (2014.6.26) JP
発明の名称 (英語) NEW MOLECULARLY TARGETED DRUG FOR TREATING MALIGNANT TUMORS
発明の概要(英語) The present invention addresses the problem of providing a new molecularly targeted drug that targets RPL29, a ribosomal protein that has enhanced expression in malignant tumor cells. With regard to a molecularly targeted drug that targets RPL29, the present invention addresses the problem of providing an antitumor drug that has a higher efficacy on RPL29. Provided is a molecularly targeted drug comprising an antibody or peptide vaccine for RPL29, said molecularly targeted drug characterized in that the drug targets a segment of 5 or more amino acid residues within the amino acid sequence that constitutes the RPL29 protein, that is, a segment contained either in SEQ ID NO. 1 of the sequence listing or in an amino acid sequence contained in SEQ ID NO. 1 that has 1 or more amino acid residue deletions, substitutions, insertions, or additions.
従来技術、競合技術の概要(英語) BACKGROUND ART
Molecular target drugs include current for malignant tumors, liver cancer or renal cancer used Sorafenib, used to patients with colorectal cancer bevacizumab or cetuximab (Bevacizumab) (Cetuximab), lung cancer (Erlotinib) gefitinib or erlotinib used (Gefitinib), such as breast cancer (Trastuzumab) trastuzumab used have been developed and are a number of drugs are, used in clinical practice. Each drug to the target material may include, for example cancer kinase, vascular endothelial growth factor (Vascular Endothelial Growth Factor: VEGF), epidermal growth factor receptor (Epidermal Growth Factor Receptor: EGFR), protein HER2(human epidermal growth factor receptor type2) and the like. However, molecular targets for drug is malignant tumor, a skin disorder or alimentary canal perforation, interstitial pneumonia, severe side effects such as death from liver failure have been reported example. Therefore, a higher level of safety has been desired the advent of molecular target drugs.
Healthy person also malignant tumor (cancer) and several thousands of daily can be said to be the cell, but are not necessarily all the onset. Autoimmune hepatitis (Autoimmune hepatitis: AIH) 0.7% / years (Aliment Pharmacol Ther 2006 liver carcinogenesis rate; 24:1197) and have been reported, chronic hepatitis C 3% / year rate of liver carcinogenesis (Ann Intern Med 1999; 131:174) are clearly inferior to low rates.
Ribosomal protein RPL29(Ribosomal protein L29) is in, (non-patent document 1) colon cancer, hepatocellular carcinoma (non-patent document 2), (non-patent document 3) gastric cancer, thyroid cancer (non-patent document 4), such as breast cancer (non-patent document 5) and a variety of malignant tumor cells when increased expression has been reported. RPL29 Is expressed inside the cell expressing the cell surface at the same time also be a membrane protein, RPL29 decreases the expression and apoptosis of the cells is increased in thatacoustic (non-patent document 6), cells induced to differentiate (non-patent document 1) are reported.
The invention relates to a molecular target drug for malignant tumors, targeting molecules target medicine RPL29 studied is reported. Daily healthy person also can be several thousands of cancer cells even though it is said that the, not necessarily all the onset of a cancer or not, autoimmune hepatitis (AIH) rate and liver carcinogenesis have been reported and 0.7% / years, 3% / years of chronic hepatitis C are clearly inferior to the low rates have been reported. Then, auto-immune disease in the patient serum, may inhibit the growth of malignant tumor cells in the presence of immunoglobulin (IgG) confirmed, targeting the RPL29 anti-RPL29 antibody disclosed (patent document 1). Anti-RPL29 antibody titers in the patent document 1 as an index of the inspection method for malignant tumor disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • 発明者(英語)
  • MIYAKE, Yasuhiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close